Compare GHY & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GHY | MRVI |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.1M | 449.6M |
| IPO Year | N/A | 2020 |
| Metric | GHY | MRVI |
|---|---|---|
| Price | $12.60 | $3.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.57 |
| AVG Volume (30 Days) | 184.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.24 | $1.67 |
| 52 Week High | $11.92 | $6.05 |
| Indicator | GHY | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 63.80 |
| Support Level | $12.30 | $3.81 |
| Resistance Level | $12.55 | $4.11 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 82.19 | 83.61 |
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.